Browsing Tag
Ophthalmology
33 posts
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy:…
Top North Georgia eye clinics merge to form North Georgia Eye Associates
Gainesville Eye Associates and North Georgia Eye Clinic, two of the major ophthalmology practices in North Georgia, have…
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around…
Health Network One acquires managed eye care provider Premier Eye Care
Health Network One, a portfolio company of H.I.G. Capital, has acquired US-based managed eye care provider Premier Eye…
Ocugen secures FDA clearance to begin OCU400 gene therapy trial: What this means for patients with retinitis pigmentosa
Find out how Ocugen’s FDA-approved OCU400 trial is shaping the future of gene therapy for retinitis pigmentosa. Read the full story today.
SPARC signs licensing deal with Visiox for two ophthalmic drug candidates
Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide…
Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals
Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic…
No drops, no plugs: How the iTEAR100 device triggers tears in 30 seconds
Olympic Ophthalmics secures FDA clearance for iTEAR100, a handheld neurostimulator that activates tear production in seconds. Find out how it could transform dry eye treatment.
Mynosys Cellular Devices raises $25m from Decheng Capital
Mynosys Cellular Devices, which manufactures the Zepto cataract surgery device, has secured $25 million in a funding round…
ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome
ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1%…